Boston Scientific Corp.

Most Recent

  • uploads///eps
    Earnings Report

    What to Expect from St. Jude Medical’s Earnings in 2Q16

    In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.

    By Sarah Collins
  • uploads///Q EPS
    Earnings Report

    Weighing in with Boston Scientific’s 4Q15 Revenues

    Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results

    On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.

    By Sarah Collins
  • uploads///piron guillaume  unsplash
    Earnings Report

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

    By Sarah Collins
  • uploads///DIABETES
    Earnings Report

    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

    By Sarah Collins
  • uploads///CASH FLOW
    Company & Industry Overviews

    How Tax Reform Affected Medtronic’s 3Q18 Performance

    Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

    By Sarah Collins
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///aid __
    Company & Industry Overviews

    Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition

    On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.

    By Sarah Collins
  • uploads///thv
    Earnings Report

    What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.

    By Sarah Collins
  • uploads///HALCYON
    Company & Industry Overviews

    Varian’s Halcyon Treatment System Sees Emerging Market Demand

    Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]

    By Sarah Collins
  • uploads///share price on Oct
    Earnings Report

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Earnings Report

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.

    By Sarah Collins
  • uploads///gks coo
    Earnings Report

    Cooper Companies Reported Mixed 2Q15 Results

    Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.

    By Gabriel Kane
  • uploads///diabetes _
    Earnings Report

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?

    For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.

    By Sarah Collins
  • uploads///doctor medical medicine health
    Earnings Report

    Boston Scientific’s 1Q18 Results: Key Highlights

    Yesterday, Boston Scientific released its 1Q18 earnings results. The company registered sales of $2.38 billion.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Abbott Laboratories’ Stock Performance after a Recent Bull Run

    On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.

    By Sarah Collins
  • uploads///stock performance
    Earnings Report

    Abbott Laboratories’ Stock Price Performance in July

    Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Has Boston Scientific Stock Performed Recently?

    Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

    By Sarah Collins
  • uploads///hospital _
    Earnings Report

    Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings

    On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.

    By Sarah Collins
  • uploads///hand __
    Company & Industry Overviews

    BSX Stock Regains Momentum after Its Recent Bearish Trend

    On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.

    By Sarah Collins
  • uploads///aerial view _
    Company & Industry Overviews

    Stryker Declines Buyout Talks with Boston Scientific

    On June 13, Stryker (SYK) said in a regulatory filing that it’s not in discussions with Boston Scientific related to its acquisition.

    By Sarah Collins
  • uploads///QCOM
    Financials

    Omega Advisors exits position in Qualcomm

    Last month, Qualcomm announced 4Q14 and fiscal 2014 earnings that missed estimates. Its revenue for 4Q14 was $6.69 billion, missing analysts’ expectations by $330 million.

    By Samantha Nielson
  • uploads///hospital _
    Company & Industry Overviews

    Boston Scientific Stock in the Week Ended September 14

    Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.

    By Sarah Collins
  • uploads///geographic strength
    Company & Industry Overviews

    How BD-Bard Acquisition Will Strengthen International Presence

    C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.

    By Sarah Collins
  • uploads///valuation
    Earnings Report

    Abbott Laboratories’s Valuation before Its 2Q16 Results

    After the release of its 1Q16 earnings results on April 20, 2016, Abbott Laboratories (ABT) was trading at a forward PE multiple in the range of 16.4x–19.3x.

    By Sarah Collins
  • uploads///microbiology _
    Company & Industry Overviews

    Illumina Stock Continues Its Bull Run

    Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

    By Sarah Collins
  • uploads///ABMD
    Company & Industry Overviews

    Examining Abiomed’s Gross Margin Trend

    In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.

    By Kenneth Smith
  • uploads///eps estimates
    Earnings Report

    What Can We Expect for Stryker’s Earnings in 2Q16?

    In 1Q16, Stryker exceeded analysts’ EPS (earnings per share) estimate of $1.20, as well as the revenue estimate of ~$2.5 billion.

    By Sarah Collins
  • uploads///BSX
    Financials

    Omega Advisors eliminates position in Boston Scientific

    Boston Scientific Corporation is a worldwide developer, manufacturer, and marketer of medical devices that are used in a broad range of interventional medical specialties

    By Samantha Nielson
  • uploads///CIM
    Financials

    Omega Advisors lowers position in Chimera Investment

    Chimera Investment invests in residential mortgage loans, residential mortgage-backed securities, real estate-related securities and various other asset classes. Chimera declared a fourth-quarter 2014 cash dividend of $0.09 per common share.

    By Samantha Nielson
  • uploads///ABT STJ product portfolio
    Company & Industry Overviews

    These Developments Impacted Abbott Laboratories the Most in Fiscal 2017

    Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Here Are the Key Growth Catalysts for Boston Scientific in 2019

    In its fourth-quarter earnings press release, Boston Scientific (BSX) reported revenues of $9.82 billion for fiscal 2018.

    By Margaret Patrick
  • uploads///surgery _
    Company & Industry Overviews

    How Is BSX Overcoming Its Urology and Pelvic Health Headwinds?

    On its first-quarter earnings conference call, Boston Scientific said that it expected its Urology and Pelvic Health business’s revenue performance to prove accretive to its revenue in the second half and the whole of 2019. The company expects the resolution of its sterilization issues and its acquisitions of NxThera and Augmenix to drive its Urology and Pelvic Health revenue in 2019.

    By Margaret Patrick
  • uploads///analysis _
    Company & Industry Overviews

    Boston Scientific or Intuitive Surgical: Which Is a Better Pick?

    Boston Scientific (BSX) and Intuitive Surgical (ISRG) are up 17.29% and 6.43%, respectively, YTD (year-to-date). To evaluate which of the two is a better pick in the long run, let’s evaluate the various pros and cons of each.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Boston Scientific or Abbott: Who Will Report More Revenue Growth?

    In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Abbott Laboratories’ Key Growth Drivers in 2019?

    On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Boston Scientific’s Free Cash Flow and Tax Rate Guidance for 2018

    On its third-quarter earnings conference call, Boston Scientific (BSX) said that it expected its adjusted free cash flow to be $1.9 billion in 2018.

    By Margaret Patrick
  • uploads///equipment _
    Company & Industry Overviews

    FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%

    Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.

    By Daniel Collins
  • uploads///equipment _
    Company & Industry Overviews

    Boston Scientific and Edward Lifesciences Settle Patent Dispute

    Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.

    By Daniel Collins
  • uploads///Chart  Healthcare
    Company & Industry Overviews

    GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth

    As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity.

    By Anirudha Bhagat
  • uploads///ABMD
    Company & Industry Overviews

    Do Analysts See Any Upside for Abiomed Stock?

    In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Exploring Abiomed’s Latest Performance Trends

    In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.

    By Kenneth Smith
  • uploads///BSX
    Company & Industry Overviews

    Why Analysts Are Mostly Positive on Boston Scientific Stock

    Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.

    By Daniel Collins
  • uploads///hypertension _
    Company & Industry Overviews

    Taking Stock of Edwards Lifesciences’ Performance

    A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///HOLX
    Company & Industry Overviews

    What Analysts Recommend for Hologic Stock

    In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///checklist _
    Company & Industry Overviews

    Baxter International: Why Investors Are Interested

    Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///Interventional Solutions
    Company & Industry Overviews

    Johnson & Johnson’s Interventional Solutions Business

    JNJ’s Interventional Solutions segment generated third-quarter net revenues of $653.0 million, compared to $553.0 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///SYk ana reco
    Earnings Report

    What Analysts Recommend for Stryker Stock

    Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

    By Kenneth Smith
  • uploads///earnings estimates
    Earnings Report

    Edwards Lifesciences’ Q3 2018 Earnings Estimates

    Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.

    By Sarah Collins
  • uploads///sales estimates
    Earnings Report

    What to Expect of Edwards Lifesciences’ Q3 2018 Sales

    Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    ABT Stock Registered a 52-Week High in October

    On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.

    By Sarah Collins
  • uploads///COMPARISON
    Company & Industry Overviews

    EW Stock Returned More than the S&P 500’s Gain in 2018

    As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    High Valuation Multiples: Is EW Stock an Expensive Bet?

    On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    Is Abbott Laboratories Trading at a High Valuation in September?

    Abbott stock has been gaining momentum recently, and its valuation has improved.

    By Sarah Collins
  • uploads///COMPARISON
    Company & Industry Overviews

    ABT Returns Almost Double the S&P 500’s Year-to-Date Gain

    As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Stock Trades at Its 52-Week High in September

    On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.

    By Sarah Collins
  • uploads///hologic recommendations
    Company & Industry Overviews

    Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock

    As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Electrophysiology Is Expected to Be a Major Asset for BSX in 2018

    In the second quarter of 2018, Boston Scientific’s (BSX) electrophysiology business reported revenue of close to $79 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Endoscopy and Urology Businesses Expected to Drive Growth at BSX

    In the second quarter, Boston Scientific’s (BSX) endoscopy business reported revenue of close to $442 million, a YoY (year-over-year) rise of ~9%.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Expect for Abiomed

    Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018.

    By Mike Benson
  • uploads///hand _
    Company & Industry Overviews

    Do Abiomed’s Valuations Look Attractive?

    Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.

    By Mike Benson
  • uploads///analysis _
    Company & Industry Overviews

    How Analysts View Becton Dickinson in August 2018

    On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65.

    By Daniel Collins
  • uploads///medic _
    Earnings Report

    Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates

    Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///cryoablation
    Company & Industry Overviews

    Assessing BSX’s Recently Acquired Cryterion Cryoablation Platform

    On July 5, Boston Scientific announced its acquisition of Cryterion Medical, which will add Cryterion’s cryoablation platform to BSX’s atrial fibrillation treatment portfolio.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Electrophysiology Business May Be a Solid Growth Driver for BSX

    In the first quarter, Boston Scientific (BSX) reported sales of close to $75 million in its electrophysiology business.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    LUX-DX ICM and WATCHMAN LAAC May Prove Solid Drivers for BSX

    Boston Scientific (BSX) is preparing to launch the LUX-DX insertable cardiac monitor (or ICM) in both the United States and Europe.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BSX Focuses on Advancing Its Cardiac Rhythm Management Portfolio

    Boston Scientific expects the results from its UNTOUCHED trial by 2020.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Spectra WaveWriter Provides Personalized Chronic Pain Therapy

    On January 11, Boston Scientific (BSX) announced that the FDA had approved its multitherapy Spectra WaveWriter SCS (spinal cord stimulation) system for providing both sub-perception and paresthesia-based therapy to patients with chronic pain.

    By Margaret Patrick
  • uploads///brain _
    Company & Industry Overviews

    Neuromodulation: A Major Growth Driver for Boston Scientific

    According to Boston Scientific’s (BSX) estimates, the market opportunity for its neuromodulation portfolio grew ~14% year-over-year in 2017 to ~$2.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How BSX Is Set to Benefit from Its nVision Medical Acquisition

    On a reported basis, Boston Scientific’s (BSX) urology and pelvic health sales rose 11.8% YoY (year-over-year) to $293 million in Q1 2018, and 9.2% YoY in constant currency.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Boston Scientific Aims to Expand Its Presence in Men’s Health

    According to Boston Scientific’s (BSX) estimates, around 110 million people around the world have been diagnosed with BPH (benign prostatic hyperplasia).

    By Margaret Patrick
  • uploads///adrien milcent  unsplash
    Company & Industry Overviews

    Urology and Pelvic Health: Key Growth Drivers for BSX

    Boston Scientific (BSX) expects the addressable market for its urology and pelvic health portfolio to grow from $3.5 billion in 2016 to $4.4 billion in 2020.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pathology, Infection Control: Boston Scientific’s Key Areas?

    Boston Scientific (BSX) currently operates the only gastrointestinal (or GI) specialized pathology lab in the United States.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Endoluminal Surgery May Be Opportunity for Boston Scientific

    In June, Boston Scientific (BSX) announced the launch of ORISE, its traction solution used in endoluminal surgery.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Boston Scientific: Standard of Care in Pancreaticobiliary Disease

    In Q1 2018, Boston Scientific’s endoscopy business reported sales of $418 million, which is a YoY growth of 10.2% on a reported basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Boston Scientific: Focused on Category Leadership in Endoscopy

    Boston Scientific (BSX) has estimated the market opportunity in pancreaticobiliary disease to be $1.4 billion in 2018 and $1.7 billion by 2021.

    By Margaret Patrick
  • uploads///hospital _
    Company & Industry Overviews

    Endoscopy: A Major Growth Area for Boston Scientific in 2018

    Boston Scientific (BSX) expects the endoscopy market to grow at a CAGR (compound annual growth rate) of 5% from 2017 to 2020.

    By Margaret Patrick
  • uploads///BSX
    Company & Industry Overviews

    Analyzing Boston Scientific’s Financial Performance

    In Q1 2018, Boston Scientific (BSX) generated sales of $2.4 billion compared to $2.2 billion in Q1 2017.

    By Kenneth Smith
  • uploads///health _
    Company & Industry Overviews

    Analyst Recommendations for Boston Scientific and Peers in June

    Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///BSX cardiology
    Company & Industry Overviews

    Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance

    Boston Scientific’s (BSX) Cardiovascular segment’s net sales increased from $851 million in Q1 2017 to $933 million in Q1 2018.

    By Kenneth Smith
  • uploads///BSX  electrophysiology
    Company & Industry Overviews

    Boston Scientific’s Electrophysiology and Neuromodulation Areas

    Worldwide revenues of Boston Scientific’s (BSX) electrophysiology business grew 20% from $64 million in Q1 2017 to $75 million in Q1 2018.

    By Kenneth Smith
  • uploads///BSX MA
    Company & Industry Overviews

    Boston Scientific’s Recent Acquisitions and What They Mean

    In April, Boston Scientific (BSX) closed two acquisitions: NxThera and nVision Medical.

    By Kenneth Smith
  • uploads///computer _
    Company & Industry Overviews

    How Much Upside Do Analysts See in Baxter Stock?

    Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///mitraclip
    Company & Industry Overviews

    MitraClip Drives Growth, Gets Reimbursement Approval in Japan

    On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?

    Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BAX May See Slight Rise in Net Profit Margins in Fiscal 2018

    In 4Q17, Baxter International (BAX) reported adjusted earnings per share close to $0.64, which represents year-over-year growth of 12.0%.

    By Margaret Patrick
  • uploads///daniel frank  unsplash
    Company & Industry Overviews

    Analysts’ March 2018 Ratings for Baxter International and Peers

    In March, 17 analysts tracked Baxter International. Three gave a “strong buy” rating, seven gave a “buy” rating, and six suggested a “hold.”

    By Margaret Patrick
  • uploads///RESOLUTE ONYX
    Company & Industry Overviews

    Medtronic Launches Its Resolute Onyx 2.0 mm DES

    On February 26, 2018, Medtronic (MDT) announced that the FDA has approved the launch of its Resolute Onyx 2.0 mm DES.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    What’s Abbott Laboratories’ Current Valuation?

    As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x.

    By Sarah Collins
  • uploads///masters hp
    Company & Industry Overviews

    ABT Gets FDA Approval for World’s Smallest Mechanical Heart Valve

    Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BSX Stock Rises More Than 2% Following EMcision Acquisition

    Boston Scientific’s recent stock performance On March 6, 2018, Boston Scientific (BSX) stock closed at $27.41, higher than its 50-day moving average of $27.15 and lower than its 200-day moving average of $27.52. As of March 7, 2018, Boston Scientific’s 52-week high was $29.93 on October 23, 2017, and its 52-week low was $24.02 on March 22, 2017. Factors […]

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street’s Recommendations and Target Prices for BSX

    Analysts’ recommendations on Boston Scientific Boston Scientific (BSX) is a leading medical technology company in the United States. The company has been a leading player in minimally invasive therapies for a range of cardiovascular and rhythm management diseases, a space that has become increasingly competitive over the years. Boston Scientific has been expanding in other areas, including endoscopy under its MedSurg […]

    By Sarah Collins
  • uploads///BSX
    Company & Industry Overviews

    Analyzing Boston Scientific’s Business Segments

    Boston Scientific (BSX) operates in three business segments that cater to seven different product categories.

    By Kenneth Smith
  • uploads///medical pic UFyCp KzY
    Company & Industry Overviews

    Boston Scientific: Analysts’ Ratings in February 2018

    In February 2018, 21 of the 26 analysts covering Boston Scientific gave it a “buy” or higher rating, while five analysts gave it a “hold” rating.

    By Kenneth Smith
  • uploads///mitg
    Earnings Report

    Medtronic’s Minimally Invasive Therapies Group in 3Q18

    Overview In fiscal 3Q18, Medtronic’s (MDT) MITG (Minimally Invasive Therapies Group) continued to perform poorly, reporting a YoY (year-over-year) decline of ~16% due to the divestiture of the company’s PMR (Patient Monitoring and Recovery) business in fiscal 2Q18. For details, please read Divestiture of a Part of Medtronic’s PMR Business to Cardinal Health. However, on a constant-currency […]

    By Sarah Collins
  • uploads///CVG
    Earnings Report

    What Drove Medtronic’s Cardiac and Vascular Group in 3Q18

    Cardiac and Vascular Group in fiscal 4Q17 Medtronic (MDT) reported total sales of ~$7.4 billion in fiscal 3Q18. Of that total, ~38% (~$2.8 billion) was contributed by Medtronic’s CVG (Cardiac and Vascular Group). CVG sales grew ~10% YoY (year-over-year) and ~7% on a constant-currency basis. US CVG sales grew ~6% YoY, while developed nation CVG sales […]

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Latest Recommendations on Boston Scientific Stock

    BSX operates in three business segments: MedSurg, Rhythm Management, and Cardiovascular.

    By Sarah Collins
  • uploads///ambulance _
    Earnings Report

    BDX’s New Reporting Structure after Bard Acquisition

    Becton, Dickinson and Company (BDX) completed the acquisition of Bard on January 29, 2018.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.